Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD9331 (Plevitrexed) Monotherapy vs Combination with Topotecan in Refractory Ovarian Cancer
NCT00014690Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pemetrexed in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AstraZeneca. Started Mar 2001; status: completed.
02
Drugs
pemetrexed
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00014690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014690.